A detailed history of Royal Bank Of Canada transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 25,295 shares of BLUE stock, worth $211,213. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,295
Previous 24,618 2.75%
Holding current value
$211,213
Previous $24,000 45.83%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.47 - $1.35 $318 - $913
677 Added 2.75%
25,295 $13,000
Q2 2024

Aug 14, 2024

BUY
$0.85 - $1.26 $11,594 - $17,187
13,641 Added 124.27%
24,618 $24,000
Q1 2024

Nov 05, 2024

SELL
$0.91 - $1.75 $12,413 - $23,871
-13,641 Reduced 55.41%
10,977 $14,000
Q1 2024

May 15, 2024

SELL
$0.91 - $1.75 $22,947 - $44,129
-25,217 Reduced 69.67%
10,977 $14,000
Q4 2023

Feb 14, 2024

BUY
$1.32 - $4.83 $13,332 - $48,783
10,100 Added 38.71%
36,194 $49,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $4.05 $20,629 - $27,665
6,831 Added 35.46%
26,094 $79,000
Q2 2023

Aug 14, 2023

BUY
$2.79 - $5.03 $3,657 - $6,594
1,311 Added 7.3%
19,263 $63,000
Q1 2023

May 15, 2023

SELL
$3.14 - $8.22 $5,827 - $15,256
-1,856 Reduced 9.37%
17,952 $57,000
Q4 2022

Feb 14, 2023

BUY
$5.77 - $8.49 $67,537 - $99,375
11,705 Added 144.45%
19,808 $137,000
Q3 2022

Nov 14, 2022

BUY
$3.75 - $7.39 $3,341 - $6,584
891 Added 12.35%
8,103 $52,000
Q2 2022

Aug 15, 2022

BUY
$2.94 - $5.23 $1,181 - $2,102
402 Added 5.9%
7,212 $29,000
Q1 2022

May 16, 2022

SELL
$4.07 - $10.6 $24,611 - $64,098
-6,047 Reduced 47.03%
6,810 $33,000
Q4 2021

Feb 14, 2022

BUY
$8.96 - $16.31 $17,588 - $32,016
1,963 Added 18.02%
12,857 $128,000
Q3 2021

Nov 15, 2021

SELL
$11.24 - $21.0 $5.11 Million - $9.54 Million
-454,354 Reduced 97.66%
10,894 $208,000
Q2 2021

Aug 16, 2021

BUY
$18.04 - $22.09 $8.39 Million - $10.3 Million
465,248 New
465,248 $14.9 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $644M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.